神经药理学报››2013,Vol. 3››Issue (6): 44-47.
王金
出版日期:
2013-12-26发布日期:
2014-06-27作者简介:
王金,男,讲师,硕士;研究方向:中药新药研究开发;Tel:+86-0313-4029305;E-mail:wangjinzym@163.com基金资助:
河北省卫生厅资助项目(No.20110173),河北省教育厅资助项目(No.Z2011304)
WANG Jin
Online:
2013-12-26Published:
2014-06-27About author:
王金,男,讲师,硕士;研究方向:中药新药研究开发;Tel:+86-0313-4029305;E-mail:wangjinzym@163.comSupported by:
河北省卫生厅资助项目(No.20110173),河北省教育厅资助项目(No.Z2011304)
摘要:帕金森病(Parkinson’s disease,PD)是以运动功能异常和非运动症状为特征的中枢神经退行性疾病。非运动症状包括睡眠障碍、神经精神病学障碍、认知功能障碍、自主神经系统障碍、胃肠道功能紊乱和感觉症状等。由于缺乏足够的认识和重视,这些症状常被忽视或误诊,严重影响到帕金森病患者的生活质量。该文对帕金森病非运动症状的表现及治疗进展做一综述。
中图分类号:
王金.帕金森病非运动症状及药物治疗研究进展[J]. 神经药理学报, 2013, 3(6): 44-47.
WANG Jin.Non-motor Symptoms of Parkinson’s Disease[J]. Acta Neuropharmacologica, 2013, 3(6): 44-47.
[1] Sara Varanese, Zoe Birnbaum, Roger Rossi, et al. Treatment of advanced Parkinson’s disease[J].Parkinsons Dis, 2011, 2010: 480260. [2] Cynthia L Commella. Sleep disturbances in Parkinson’s disease[J] .Curr Neurol Neurosci Rep, 2003, 10(3):173–180. [3] I Eisensehr, R linke, S Noachtar, et al. Reduced striatal dopamine transports in idiopathic rapid eye movement sleep behaviour disorder.comparasion with parkinson’s disease[J]. Brain, 2000, 123(Pt6): 1155-1160. [4] B F Boeve, M H Silber, J E Parisi, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism[J]. Neurology, 2003, 61(1): 40–45. [5] J F Gagnon, M A Bedard, M L Fantini, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease [J]. Neurology, 2002, 59(4):585–589. [6] R D Abbott, G W Ross, L R White, et al. Excessive daytime sleepiness and the future risk of Parkinson’s disease [J]. Mov Disord, 2005, 20(10):S101. [7] Thomas Müller. Drug therapy in patients with Parkinson’s disease [J]. Translational Neurodegeneration, 2012, 1:10. [8] Sze-Ee Soh, Meq E Morris, Jennifer L McGinley. Determinants of health-related quality of life in Parkinson’s disease: a systematic review [J].Parkinsonism Relat Disord, 2011, 17(1):1-9. [9] J Schwarz, P Odin, C Buhmann, et al. Depression in Parkinson’s disease [J]. J Neurol, 2011, 258(suppl 2):S336-S338. [10] Laura Marsh. Neuropsychiatric aspects of Parkinson’s disease [J]. Psychosmatics, 2000, 41(1):15-23. [11] 周晓雯,苏朝芬,罗焕敏. 线粒体与神经退行性疾病[J].神经药理学报,2011,1(3):41-46. [12] 薛占霞,彭亮. 情感性精神障碍疾病治疗药物的研究现状[J].神经药理学报,2011,1(3):55-64. [13] Ziemssen Tjalf, Heinz Reichmann. Non-motor dysfunction in Parkinson’s disease [J]. Parkinsonism related disorder, 2007, 13(6):323332. [14] I H Richard, R B Schiffer, R Kurlan. Anxiety and Parkinson’s disease [J]. J Neuropsychiatry Clin Neurosci, 1996, 8:383-392. [15] Manmohan Mehndiratta, Rohit K Garg, Sanjay Pandey. Nonmotor symptom complex of Parkinson's disease--an under-recognized entity [J]. J Assoc Physicians India, 2011, 59: 302-308. [16] E C Lauterbach, R C Duvoisin. Anxiety disorders in familial parkinsonism [J]. Am J Psychiatry, 1992, 148(2):274. [17] Jennifer G Goldman. New thoughts on thought disorders in Parkinson’s disease: review of current research strategies and challenges [J]. Parkinsons Dis, 2011, 2011:675630. [18] 王新,于谭方,王平. 帕金森病患者非运动症状的研究进展 [J].国际神经病学神经外科杂志,2011(38)2:139-142. [19] Angie A Kehagia, Roger A Baker, Trevor W Robbins. Neuropsychological and clinical heterogeneity of congnitive impariment and dementia in patients with Parkinson’s disease [J]. Lancet Neurol, 2010, 9(12): 1200-1213. [20] Murat Emre. Demetia associated with Parkinson’s disease [J]. Lancet Neurol, 2003, 2(4): 229–237. [21] Lehana Yeo, Rajindra Singh, Mohan Gundeti, et al. Urinary tract dysfunction in Parkinson’s disease: a review [J]. Int Urol Nephrol, 2012, 44(2):415-424. [22] Michael S Okun, Benjamin L Walter, William M McDonald, et al. Beneficial effects of testosterone replacement for the non motor symptoms of Parkinson’s disease [J]. Arch Neurol, 2002, 59(11):1750-1753. [23] Francesca Romana Pezzella, Carlo Colosimo, Nicola Vanacore, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease [J].Mov Disord, 2005, 20(1):77-81. [24] R D Abbott, H Petrovitch, L R White, et al. Frequency of bowel movements and future risk of Parkinson’s disease[J]. Neurology, 2001, 57(3):456-462. [25] Quinn NP, Koller WC, Lang AE, et al. Painful Parkinson’s disease [J].Lancet, 1996, 1:1366-1369. [26] W Poewe. Nonmotor symptoms in Parkinson’s disease. In: Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders [M]. 5th. Philadelphia: Lippincott Williams and Wilkins, 2007:67-76. [27] Andrew Siderowf, Danna Jdennings, James Connolly, et al. Risk factors for Parkinson’s disease and impaired olfaction in relatives of patients with Parkinson’s disease[J]. Mov Disord, 2007, 22(15):2249-2255. [28] G Webster Ross, Helen Petrovitch, Robert D Abbott, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease [J]. Ann Neurol, 2008, 63(2):167-173. |
[1] | 禹文峰,李成朋,韩飞,官志忠.硫辛酸抑制AIF 介导的非Caspase 凋亡通路对多巴胺能神经元的保护机制[J]. 神经药理学报, 2018, 8(2): 40-40. |
[2] | 高志红,左亚奇,张晓丽.黄芪甲苷诱导骨髓间充质干细胞治疗帕金森病的新思路[J]. 神经药理学报, 2017, 7(5): 39-44. |
[3] | 万叶,郭春燕,李永民.中药在帕金森病领域的研究进展[J]. 神经药理学报, 2017, 7(4): 36-42. |
[4] | 张丽娜,张欣,薛娟,张丹参.中药对中枢神经退行性疾病信号通路影响的研究进展[J]. 神经药理学报, 2017, 7(3): 33-42. |
[5] | 余汇,钟佳宏,钟秋萍,汪海涛,王文雅, 徐江平.Tideglusib 对MPP+ 诱导的SH-SY5Y 细胞凋亡的保护作用及其机制研究[J]. 神经药理学报, 2017, 7(2): 61-61. |
[6] | 钟佳宏,汪海涛,徐江平.α - 突触核蛋白与帕金森病[J]. 神经药理学报, 2017, 7(2): 62-62. |
[7] | 杨明艳,王冬雪,王玥,毕玉莹,毕田田.帕金森病轻度认知障碍[J]. 神经药理学报, 2017, 7(2): 63-63. |
[8] | 汪林芳,黄术兵,徐一达,崔春,申延琴.马钱苷对MPTP 诱导的PC12 细胞自噬的作用研究[J]. 神经药理学报, 2016, 6(5): 14-21. |
[9] | 张美金,王莎莎,张钊,陈乃宏,胡金凤.核转录因子Nrf2 在帕金森病中的作用[J]. 神经药理学报, 2016, 6(1): 35-40. |
[10] | 娄钰霞,张钊,王真真,姜懿纳,张毅,李林,陈乃宏.帕金森病相关基因DJ-1 与氧化应激[J]. 神经药理学报, 2016, 6(1): 58-64. |
[11] | 高杨,段冷昕.细胞自噬在帕金森病和阿尔茨海默病中的研究进展[J]. 神经药理学报, 2015, 5(3): 22-27. |
[12] | 郝军荣,沈丽霞.蛋白质组学在帕金森病研究中的应用研究进展[J]. 神经药理学报, 2015, 5(3): 28-35. |
[13] | 姜懿纳, 陈乃宏.帕金森病致病基因Parkin的研究进展[J]. 神经药理学报, 2015, 5(3): 36-45. |
[14] | 吴志刚,沈丽霞.帕金森病患者下尿路功能障碍的治疗进展[J]. 神经药理学报, 2014, 4(4): 36-41. |
[15] | 曹欣欣,王书华.金莲花药理活性及临床应用研究进展[J]. 神经药理学报, 2014, 4(4): 59-64. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||